These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25576329)

  • 41. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
    Devendra D; Gohel B; Bravis V; Hui E; Salih S; Mehar S; Hassanein M
    Int J Clin Pract; 2009 Oct; 63(10):1446-50. PubMed ID: 19678856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
    Kothny W; Lukashevich V; Foley JE; Rendell MS; Schweizer A
    Diabetologia; 2015 Sep; 58(9):2020-6. PubMed ID: 26067186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
    Shimodaira M; Niwa T; Nakajima K; Kobayashi M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):223-8. PubMed ID: 25809193
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials.
    Schweizer A; Dejager S; Foley JE; Shao Q; Kothny W
    Diabetes Obes Metab; 2011 Jan; 13(1):55-64. PubMed ID: 21114604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
    Chatterjee S; Chatterjee S
    Am J Ther; 2015; 22(3):195-8. PubMed ID: 23665884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
    Haidinger M; Werzowa J; Voigt HC; Pleiner J; Stemer G; Hecking M; Döller D; Hörl WH; Weichhart T; Säemann MD
    Trials; 2010 Oct; 11():91. PubMed ID: 20925938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.
    Göke R; Bader G; Dworak M
    Diabetes Ther; 2014 Jun; 5(1):183-91. PubMed ID: 24643724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2014 Apr; 74(5):587-610. PubMed ID: 24638989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
    Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
    Pi-Sunyer FX; Schweizer A; Mills D; Dejager S
    Diabetes Res Clin Pract; 2007 Apr; 76(1):132-8. PubMed ID: 17223217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
    Blonde L; Dagogo-Jack S; Banerji MA; Pratley RE; Marcellari A; Braceras R; Purkayastha D; Baron M
    Diabetes Obes Metab; 2009 Oct; 11(10):978-86. PubMed ID: 19614942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.